AN-9 and Daunorubicin Help Mice with Leukemia Live Longer
Author Information
Author(s): T Kasukabe, A Rephaeli, Y Honma
Primary Institution: Saitama Cancer Center Research Institute
Hypothesis
Can the combination of pivalyloxymethyl butyrate (AN-9) and daunorubicin improve survival in mice with monocytic leukaemia?
Conclusion
The combination of AN-9 and daunorubicin significantly prolonged the survival of mice inoculated with monocytic leukaemia cells.
Supporting Evidence
- AN-9 alone prolonged survival in a dose-dependent manner.
- Combination treatment with AN-9 and daunorubicin resulted in a significant increase in survival time compared to either treatment alone.
- AN-9 induced apoptosis in leukaemia cells, while butyrate did not.
Takeaway
Researchers found that a new drug called AN-9, when used with another drug called daunorubicin, helped mice with leukemia live longer.
Methodology
Mice were inoculated with monocytic leukaemia cells and treated with AN-9 and daunorubicin to assess survival times.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
Inbred SL strain female mice, aged 8-10 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website